OncoC4 was founded by Yang Liu, Pan Zheng in 2020.

Who are OncoC4's investors?

OncoC4's investors include 3E Bioventures Capital, HM Venture Partners.

How much funding has OncoC4 raised?

OncoC4 has disclosed $50M raised across 1 of its 2 known rounds.

Where is OncoC4 headquartered?

OncoC4 is headquartered in Rockville, US.

OncoC4

Rockville, US · Founded 2020 · Delaware corporation · 2 known investors

Find your way into OncoC4

217 people in our graph share verified history with the OncoC4 team — schools, employers, funds. One of them is your warm intro.

Anthony Philippakisunlockedknows Pan Zheng · together at Yale University (overlapped)

×9knows the team · via Yale University

×2knows the team · via University of Michigan

OncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders. It advances its pipeline through internal R&D and external partnerships, including a collaboration with BioNTech to develop and commercialize gotistobart.

Biotech Healthtech

Founders & leadership

OncoC4 was founded in 2020 by Yang Liu and Pan Zheng.

Yang LiuinCo-founder · Chairman, CEO and CSO

Pan Zheng inCo-founderPan Zheng co-founded OncoImmune and served as Chief Medical Officer until its acquisition by Merck, where he led clinical trial design and execution; he holds board certification in pathology and has held academic faculty positions at Ohio State University, University of Michigan, and University of Maryland School of Medicine. At OncoC4, he leads clinical development of immunotherapy treatments for cancer.

Martin DevenportNamed on SEC filing

Michael FlaschenNamed on SEC filing

Investors · 2

3E Bioventures CapitalPalo Alto

HM Venture PartnersSan Francisco

Funding

SEC filings, press & company announcements

$50M disclosed across 1 of 2 rounds · 2020–2025

$50MSeries BOct 2025 · 2 sources
Source ↗

▶$50MofferedJan 2021 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Martin DevenportExecutive Officer
Yang LiuExecutive Officer, Director
Michael FlaschenDirector

Offering amount: $50M
First sale: Dec 2020
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Oup26 shared keywordsOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.

Companies competing with OncoC4 for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates - BioSpacebiospace.com · Oct 2025

OncoC4 Raises Nearly $50M in Series B Fundingfinsmes.com · Oct 2025

Sell or Invest in OncoC4 Stock Pre-IPOnasdaqprivatemarket.com · Jun 2025

Frequently asked questions

What does OncoC4 do?: OncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders. It advances its pipeline through internal R&D and external partnerships, including a collaboration with BioNTech to develop and commercialize gotistobart.
Who founded OncoC4?: OncoC4 was founded by Yang Liu, Pan Zheng in 2020.
Who are OncoC4's investors?: OncoC4's investors include 3E Bioventures Capital, HM Venture Partners.
How much funding has OncoC4 raised?: OncoC4 has disclosed $50M raised across 1 of its 2 known rounds.
Where is OncoC4 headquartered?: OncoC4 is headquartered in Rockville, US.